Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors

NCT06132217 is registered in ClinicalTrials.gov with Shanghai Runshi Pharmaceutical Technology Co., Ltd as lead sponsor.

NCT NCT06132217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06132217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study To Evaluate The Safety, Tolerability, Pharmacokinetic Profile And Preliminary Efficacy Of Simmitinib Plus SG001 in Patients With Advanced Solid Tumors
Lead sponsor
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
January 30, 2024
Completion date
January 30, 2027
Enrollment
168 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor